The US-UK trade deal signed in December is facing a fresh post-mortem, with new analysis suggesting its pharmaceutical provisions could cost the NHS up to £45bn over ten years and cause nearly 300,000 excess deaths. Headlines celebrate tariff-free British drug exports; the data points to a very expensive bill at home.

Trade Routes

• United States: President Trump's aggressive drug-pricing strategy is the driving force, trading market access for higher UK...